Know Cancer

forgot password

A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia

Phase 3
18 Years
Open (Enrolling)
Acute Myeloid Leukemia (AML)

Thank you

Trial Information

A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia

The study investigates the new nucleoside analogue derivative, elacytarabine, as treatment
for patients with relapsed or refractory Acute Myeloid Leukemia (AML). To be included in the
study, patients must have failed to respond to two or three different therapies for AML, or
have obtained remission but then relapsed within a relatively short period of time. Patients
of age ≥ 65 with adverse cytogenetics can be included in the study after having received
one and up to three previous induction/re-induction therapies.

Elacytarabine is an investigational drug which is not commercially available. It is the
elaidic acid ester derivative of cytarabine. Cytarabine is routinely used in the treatment
of patients with AML. A substantial portion of AML patients have a deficient uptake of
cytarabine, often explained by lack of a transport protein (hENT1) in the leukemic cell
membrane. Due to the elaidic acid (a naturally occurring fatty acid), cellular uptake of
elacytarabine is independent of this transport protein.

Patients included in the study will be randomized to elacytarabine or control treatment.
Since there is no standard therapy for relapsed or refractory AML, there is a list of 7
control treatments and the investigator has to choose one that is locked before

Elacytarabine is given as a continuous infusion over five days, followed by a rest period of
minimum two weeks. Investigator's choice treatment is given according to the specific

After each course response evaluation and a decision on further treatment will be made.

Repeated courses of elacytarabine and control treatment might be needed to attain and/or
maintain complete remission or clinical benefit.

After the end of study treatment, all patients will be followed for relapse and survival.

Inclusion Criteria:

- 18 years of age or older

- Confirmed diagnosis of AML according to WHO classification (excluding acute
promyelocytic leukaemia) who have received two or three previous
induction/re-induction regimens or patients of age ≥ 65 with adverse cytogenetics who
have received 1-3 previous induction/re-induction regimens. One of the (re-)induction
regimens could be stem cell transplantation (SCT) for achievement of remission.
Maintenance and consolidation (including SCT) may have been given, but are not
counted as previous regimens.

- Bone marrow aspirates and/or biopsies must contain > 5 % leukaemic blast cells or
patient must have biopsy-proven extramedullary AML, or patient's peripheral blood
shows occurrence of leukaemic blast cells

- Patients must

- have never attained CR or CRi (primary refractory), or

- have failed initial induction therapy, and have attained CR or CRi after salvage
therapy(ies), and then relapsed within < 6 months, or

- have attained CR or CRi after initial induction therapy and relapsed within <12
months, and failed to respond to salvage therapy(ies), or

- have relapsed after the latest CR or CRi within < 6 months

- Patients younger than 65 years should have received previous treatment with

- Patients must have recovered from previous bone marrow and/or stem cell
transplantation to a stage that the patient can tolerate the study treatment. There
is no restriction on number of regimens or type of treatment administered for
maintenance or consolidation during previous stages of the disease

- ECOG performance status (PS) of 0 - 2

- Women of child-bearing potential must have a negative serum or urine pregnancy test
within 2 weeks prior to treatment start

- Male and female patients must use acceptable contraceptive methods for the duration
of time on study, and males also for 3 months after the last elacytarabine dose

- Capable of understanding and complying with protocol requirements, and must be able
and willing to sign a written informed consent form

Exclusion Criteria:

- A history of allergic reactions to egg. A history of allergic reactions of CTCAE
grade 3 or 4 to cytarabine

- Persistent clinically significant toxicities from previous chemotherapy

- A cancer history that, according to the investigator, might confound the assessment
of the study endpoints

- Known positive status for human immunodeficiency virus (HIV)

- Pregnant and nursing patients

- Uncontrolled intercurrent illness including, but not limited to, uncontrolled
infection, or psychiatric illness/social situations that would limit compliance with
study requirements

- Impairment of hepatic or renal function to such an extent that the patient, in the
opinion of the investigator, will be exposed to an excessive risk if entered into
this clinical study

- Active heart disease including myocardial infarction within previous 3 months,
symptomatic coronary artery disease, arrhythmias not controlled by medication, or
uncontrolled congestive heart failure. Any New York Heart Association (NYHA)
functional classification grade 3 or 4

- Applicable only for patients for whom an anthracycline is part of the selected
control treatment: Left ventricular ejection fraction (LVEF) must be ≥ 45 % as
measured by MUGA scan or 2D ECHO within 14 days prior to start of therapy. Either
method is acceptable for measuring LVEF

- Applicable only for patients for whom an anthracycline is part of the selected
control treatment: The patient should tolerate minimum one course of combination

- Any anti-leukaemic agents within the last 3 weeks. Hydroxyurea,however, is allowed
for up to 12 hours prior to study treatment

- Any investigational treatment within the last 14 days

- Any medical condition which in the opinion of the investigator places the patient at
an unacceptably high risk for toxicities

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall survival

Outcome Description:

Time from date of randomisation until the date of death

Outcome Time Frame:

Until 300 events occur

Safety Issue:


Principal Investigator

David Rizzieri, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Duke University Medical Center, Durham, NC, USA


United States: Food and Drug Administration

Study ID:




Start Date:

June 2010

Completion Date:

June 2013

Related Keywords:

  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukaemia
  • AML
  • Haematology
  • Investigator's Choice
  • Elacytarabine
  • Refractory or relapsed AML
  • Phase III
  • Randomized
  • CP4055-306
  • Elacyt
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid



New York Medical College Valhalla, New York  10595
Western Pennsylvania Hospital Pittsburgh, Pennsylvania  15224
Rush University Medical Center Chicago, Illinois  60612-3824
USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California  90033-0804
Duke University Medical Center Durham, North Carolina  27710
Northwestern University Chicago, Illinois  60611
Memorial Sloan-Kettering New York, New York  
Northern New Jersey Cancer Associates Hackensack, New Jersey  07601
Sarah Cannon Research Institute Nashville, Tennessee  37203
Scripps Cancer Center Clinical Research San Diego, California  92121
The Jewish Hospital Cincinnati, Ohio  45236
St. Francis Hospital and Health Center Beech Grove, Indiana  46107
The Blood and Marrow Transplant Group of GA Atlanta, Georgia  30342
St. Francis Hospital Greenville, South Carolina  29601
UCLA School of Medicine, Division of Hematology/Oncology Los Angeles, California  90095
Rocky Mountain Blood and Bone Marrow Transplant Program Denver, Colorado  80218
Shands at the University of Florida Gainesville, Florida  32610
Winship Cancer Institute at Emory Atlanta, Georgia  30322
University of Iowa Hopsitals Iowa City, Iowa  52242
LSU Health Sciences Center, Shreveport, Louisiana  71103
New York Presbyterian Hospital, Weill-Cornell Medical College New York, New York  10021
Wake Forest University, Health Sciences Section on Hematology and Oncology Winston-Salem, North Carolina  27157-1082
Froedtert Hospital, Medical College of Wisconsin Milwaukee, Wisconsin  53226